For questions about content or obtaining CME credit, please contact the Endocrine Society at www.education.endocrine.org/contact.
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Director, Diabetes Clinical Research
Brigham and Women’s Hospital
Faculty
Harvard Medical School
Boston, Massachusetts
Scientific Director
Manager, Editorial Operations
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for endocrinologists (physicians and fellows), internists, primary care physicians, endocrine nurses, and other advanced practice professionals who care for patients with T2D.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by The Endocrine Society and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 29, 2020, through December 28, 2021:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate.
After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page.
Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Commentary by Dr. Vinod Chandran on using interleukin inhibitors secukinumab and guselkumab for axial manifestations of psoriatic arthritis, from CCO
Commentary from Dr Jim Treat on counseling parents and children about pros and cons of systemic therapy for pediatric plaque psoriasis, from CCO
CME for CCO on when to use interleukin inhibitors in psoriatis arthritis: biologic DMARD or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab
CCO slides on when to use interleukins inhibitors in psoriatis arthritis: biologic dmard or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.